cash flow reconciliationreview2024-12-31
Operating, investing and financing flows differ from the reported change in cash by 10100000, beyond tolerance 1242000.00.
Revenue
$651.00M
Fiscal year ended 2026-06-30Operating income
$72.60M
Fiscal year ended 2026-06-30Free cash flow
$66.70M
Fiscal year ended 2026-06-30BIO-RAD LABORATORIES, INC. (BIO) reported revenue of $651.00M and net income of $371.40M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIO-RAD LABORATORIES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | $585.40M | $667.50M | $649.70M | $638.50M | $610.80M |
| Cost of revenue | $305.20M | $282.70M | $348.00M | $309.60M | $306.30M | $279.40M | $325.60M | $293.80M | $283.40M | $284.90M |
| Gross profit | $345.80M | $309.40M | $345.20M | $343.40M | $345.30M | $306.00M | $342.00M | $355.90M | $355.10M | $325.90M |
| Operating income | $72.60M | $34.10M | -$118.90M | $65.30M | $77.10M | $23.70M | $58.30M | $64.50M | $101.50M | $44.60M |
| Net income | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | $64.00M | -$715.80M | $653.20M | -$2.17B | $383.90M |
| Research & development | $61.20M | $62.90M | $70.30M | $71.30M | $60.50M | $73.50M | $79.60M | $91.00M | $58.90M | $66.40M |
| Weighted-average diluted shares | shares 26.81M | shares 26.96M | Unavailable | shares 26.92M | shares 27.23M | shares 27.96M | Unavailable | shares 27.98M | shares 28.40M | shares 28.54M |
| Pretax income | $542.10M | -$689.80M | $929.20M | -$431.10M | $414.00M | $83.40M | -$908.90M | $861.60M | -$2.79B | $491.10M |
| Income tax expense | $170.70M | -$162.70M | $209.20M | -$89.20M | $96.20M | $19.40M | -$193.10M | $208.40M | -$620.80M | $107.20M |
| Diluted EPS | $13.85 | $-19.55 | Unavailable | $-12.70 | $11.67 | $2.29 | $-25.57 | $23.34 | $-76.26 | $13.45 |
| Selling, general & administrative | $212.00M | $212.40M | $221.00M | $206.80M | $207.70M | $208.80M | $204.00M | $200.40M | $194.70M | $214.90M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $517.00M | $507.20M | $529.80M | $395.80M | $369.30M | $521.40M | $488.10M | $410.40M | $406.90M | $433.30M |
| Total assets | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B | $9.69B | $12.61B |
| Current assets | $3.02B | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B | $3.06B | $3.06B | $3.06B |
| Total liabilities | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B | $2.91B | $3.56B |
| Current liabilities | $961.30M | $917.00M | $517.00M | $522.30M | $548.90M | $506.60M | $467.80M | $497.94M | $486.96M | $466.15M |
| Total equity incl. NCI | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B | $6.78B | $9.05B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $780.60M | $770.50M | $740.70M | $783.20M | $798.80M | $790.10M | $760.00M | $804.28M | $803.69M | $783.37M |
| Accounts receivable | $441.80M | $426.20M | $460.60M | $464.70M | $469.90M | $424.70M | $452.50M | $461.94M | $445.51M | $444.81M |
| Goodwill | $574.30M | $577.10M | $579.80M | $578.70M | $581.60M | $414.60M | $410.50M | $415.10M | $412.12M | $412.82M |
| Long-term debt | $803.00M | $802.90M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Accounts payable | $143.50M | $133.10M | $129.00M | $128.80M | $139.30M | $137.90M | $122.30M | $122.18M | $126.69M | $102.75M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.70M | $108.10M | $164.90M | $120.90M | $116.50M | $129.90M | $124.20M | $163.60M | $97.60M | $69.80M |
| Capital expenditures | $32.00M | $30.00M | $45.80M | $31.70M | $45.70M | $34.40M | $42.90M | $40.20M | $42.30M | $40.20M |
| Investing cash flow | -$66.70M | -$93.20M | -$34.20M | -$43.00M | -$115.40M | $2.90M | -$30.50M | -$55.70M | -$30.90M | -$43.10M |
| Financing cash flow | -$27.60M | -$44.00M | $3.30M | -$52.50M | -$136.30M | -$97.70M | -$26.20M | -$96.00M | -$96.60M | $0 |
| Net change in cash | $9.80M | -$23.20M | $134.00M | $26.50M | -$151.40M | $33.30M | $77.60M | $4.50M | -$26.10M | $29.40M |
| Stock-based compensation | $14.50M | $15.00M | $15.90M | $14.90M | $11.90M | $15.30M | $16.40M | $15.60M | $15.00M | $15.30M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $31.50M | $47.80M | $0 | $53.40M | $140.20M | $101.90M | $0 | $97.90M | $101.00M | $4.70M |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $66.70M | $78.10M | $119.10M | $89.20M | $70.80M | $95.50M | $81.30M | $123.40M | $55.30M | $29.60M |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% | 55.6% | 53.4% |
| Operating margin | 11.2% | 5.8% | -17.2% | 10.0% | 11.8% | 4.0% | Unavailable | 9.9% | 15.9% | 7.3% |
| FCF margin | 10.2% | 13.2% | 17.2% | 13.7% | 10.9% | 16.3% | 12.2% | 19.0% | 8.7% | 4.8% |
| SBC / revenue | 2.2% | 2.5% | 2.3% | 2.3% | 1.8% | 2.6% | Unavailable | 2.4% | 2.3% | 2.5% |
| Current ratio | 3.14x | 3.21x | 5.62x | 5.44x | 5.12x | 5.99x | 6.48x | 6.14x | 6.28x | 6.57x |
| Revenue YoY growth | -0.1% | 1.1% | 3.9% | 0.5% | 2.1% | -4.2% | -2.0% | 2.8% | -6.3% | -9.8% |
| Net margin | 57.1% | Unavailable | 103.9% | -52.4% | 48.8% | Unavailable | -107.2% | 100.5% | Unavailable | Unavailable |
| R&D / revenue | 9.4% | 10.6% | 10.1% | 10.9% | 9.3% | 12.6% | Unavailable | 14.0% | 9.2% | 10.9% |
| CapEx / revenue | 4.9% | 5.1% | 6.6% | 4.9% | 7.0% | 5.9% | Unavailable | 6.2% | 6.6% | 6.6% |
| Long-term debt / equity | 0.11x | Unavailable | 0.16x | 0.18x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 31.5% | Unavailable | 22.5% | Unavailable | 23.2% | 23.3% | Unavailable | 24.2% | Unavailable | 21.8% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Reconciliation checks needing review
4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2023-12-31
Operating, investing and financing flows differ from the reported change in cash by 6491000, beyond tolerance 2005730.00.
cash flow reconciliationreview2022-12-31
Operating, investing and financing flows differ from the reported change in cash by 18167000, beyond tolerance 1000000.
balance equationreview2022-09-30
Difference 23862000 exceeds tolerance 12058462.000. Presentation or filing-vintage differences need review.